Park National Corp OH boosted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 4.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 35,503 shares of the biopharmaceutical company’s stock after acquiring an additional 1,420 shares during the period. Park National Corp OH’s holdings in Bristol-Myers Squibb were worth $1,800,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in BMY. Private Ocean LLC acquired a new position in shares of Bristol-Myers Squibb during the first quarter valued at about $28,000. Endurance Wealth Management Inc. raised its position in shares of Bristol-Myers Squibb by 119.6% during the second quarter. Endurance Wealth Management Inc. now owns 918 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 500 shares during the last quarter. HMS Capital Management LLC acquired a new position in shares of Bristol-Myers Squibb during the second quarter valued at about $45,000. Global Trust Asset Management LLC raised its position in shares of Bristol-Myers Squibb by 251.1% during the second quarter. Global Trust Asset Management LLC now owns 3,511 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 2,511 shares during the last quarter. Finally, Evolution Wealth Advisors LLC acquired a new position in shares of Bristol-Myers Squibb during the second quarter valued at about $50,000. 80.16% of the stock is owned by hedge funds and other institutional investors.
NYSE:BMY traded up $0.12 during mid-day trading on Thursday, hitting $49.33. The company’s stock had a trading volume of 3,230,853 shares, compared to its average volume of 9,082,700. Bristol-Myers Squibb Co has a fifty-two week low of $42.48 and a fifty-two week high of $63.69. The company has a current ratio of 3.88, a quick ratio of 3.75 and a debt-to-equity ratio of 1.51. The company has a market capitalization of $82.95 billion, a price-to-earnings ratio of 12.39, a P/E/G ratio of 2.49 and a beta of 0.72. The stock has a fifty day moving average of $48.63 and a 200-day moving average of $46.99.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be paid a dividend of $0.41 per share. The ex-dividend date of this dividend is Thursday, October 3rd. This represents a $1.64 annualized dividend and a yield of 3.32%. Bristol-Myers Squibb’s dividend payout ratio is 41.21%.
A number of research analysts have recently commented on BMY shares. Bank of America upped their price objective on shares of Bristol-Myers Squibb from $46.00 to $49.00 and gave the company a “neutral” rating in a research report on Tuesday, September 3rd. ValuEngine raised shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a research report on Monday, August 26th. TheStreet raised shares of Bristol-Myers Squibb from a “c+” rating to a “b-” rating in a research report on Wednesday, September 18th. JPMorgan Chase & Co. set a $62.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research report on Friday, September 13th. Finally, Atlantic Securities raised shares of Bristol-Myers Squibb from a “neutral” rating to an “overweight” rating and set a $63.00 price target for the company in a research report on Wednesday, August 14th. One research analyst has rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Hold” and a consensus target price of $55.74.
In other news, Director Robert J. Bertolini acquired 11,000 shares of the firm’s stock in a transaction on Wednesday, July 31st. The shares were purchased at an average cost of $44.72 per share, with a total value of $491,920.00. Following the completion of the purchase, the director now owns 11,397 shares of the company’s stock, valued at $509,673.84. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
Recommended Story: What is a capital gain?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.